Job Ratings - rate as often as your feeling about your job changes

02/19/24
industry:
company:
job rating:
1
Bad managers, poor experts. Worse if both in one person, for example g v
02/13/24
industry:
job title:
TFE
company:
job rating:
1
Worked for Medtronic for over 20 years. Never had a manager that was helpful. Most managers were neglectful, unaware of awards that were achieved or business that was won. Every anniversary milestone was ignored (5, 10, 15, and 20 years). Managers will meet with you once or twice a year. There was little opportunity for growth and once Earl Bakken passed away, the company culture became non existent. I tell everyone I know about my time there. I know I gave it my all for the company and no one cared.
02/12/24
industry:
company:
job rating:
3
Bad company culture
01/31/24
industry:
company:
job rating:
2
Analogy: Like in Kite Biomarin called Roche to send the cavalry to rescue the company. As in Kite it is being done by headcount reduction. Jeff A is a prominent example. Some executive and senior vice-presidents would go soon since they do not contribute but interfere by looking busy. Stock market is not impressed. Rarely companies ask the capable people who already left to return and help rebuild. Rather we may expect people streaming from Genentech and Roche following the CEO. However, they do not have right experience to match the Biomarin niche. Contraction expected, possibly 15% reduction in workforce
01/29/24
industry:
company:
job rating:
1
New CEO came from Roche and quickly decided to lay off staff. Gilead had no understanding of cell therapy and Roche person does not bring such experience. CAR T therapy at Kite was in trouble already under previous CEO. Now the CAR T therapy is facing multiple headwinds, so difficulties for Kite and Gilead have amplified. Th easiest solution is to layoff staff. Layoffs started in 2023 and will continue beyond the original announced number. Bad prospects for Kite and Gilead. New CEO would not help much.
01/28/24
industry:
job title:
Executive asst
company:
job rating:
1
The management leadership has bullied everyone wit explosive rants
01/24/24
industry:
company:
job rating:
1
Haven for many underperformers. Their main occupation is protecting a job. National connections count in hiring and career. Still it is too big to fail organization.
01/20/24
industry:
company:
job rating:
1
Too many useless vice-presidents and senior directors.
01/19/24
industry:
company:
job rating:
1
Temporarily enlarged Board of Directors? The temporary ones are experienced in M&A process. Plus new CEO with Roche connection. Due to ongoing layoffs in pharma and biotech expect the layoff to prepare ground for M&A. Obvious candidate to take over is Roche. But there were such rumors in the past and stock peaked at 126 so some bmrn insiders could sell it and make a fortune. Current rumor might be more real. Roche has a trojan horse placed in the company. In any way it looks like a preparation for M&A. Who will be a taker? Some analysts show market price at 80-85, others at around 100. No one is talking 120-130 anymore. Not good for bmrn insiders hoping to make it big, unless they have tons of stock. Portfolio and pipeline look modest. For workforce this is uncertain time. The best have already left. New candidates may come from CMO organizations of dubious quality
01/18/24
industry:
company:
job rating:
2
Bayer restructuring. Means loss of jobs. CEO could restructure himself first, if the company does not perform.
01/17/24
industry:
company:
job rating:
2
High quality managers and scientists have left. Others hang around. The replacements will be low cost, likely on working visas staying temporarily. No commitment, just to pickup some information for interviewing elsewhere.
01/13/24
industry:
company:
job rating:
1
Company is still confused about directions to follow. Hiring is useless.
01/11/24
industry:
company:
job rating:
7
7
01/06/24
industry:
company:
job rating:
1
Top management needs to be replaced, followed by incompetent middle level. The top managers have been useless preoccupied with how to protect their positions and at the same time minimizing their responsibilities. They could not manage the parts of organization they were put in charge of. But watch who will be coming. Roche-Genentech buddies or transition opportunists including international travelers. The CEO to be watched.
01/05/24
industry:
company:
job rating:
3
Finally the white elephant may start moving
01/02/24
industry:
company:
job rating:
1
The CEO office in Brisbane will be kept. To stay close to Roche-Genentech. Under the masters eye.
12/29/23
industry:
company:
job rating:
1
Roche is using Genentech in many ways. Like a source of incapable people to other organizations. Can be for competitive advantage.
12/28/23
industry:
company:
job rating:
1
Roche ordered Genentech to work on application of AI in drug discovery. At Roche no one really understands it, but to their surprise Genentech is not up to the task after years of dependency on Roche.The made an agreement with Invidia who will be the real beneficiary by familiarizing itself with this domain.
12/23/23
industry:
company:
job rating:
1
organization is filled with incompetent management scooped from the bottom barrel of the talent pool at other companies and relies on heroics from individual contributors to carry the burden of incometent managers.
12/20/23
industry:
company:
job rating:
3
new ceo is interviewing existing vice-presidents to see who would stay and who has to go. This is under pretext to introduce himself and know them better. Considerations for external candidates are already in place.

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.